Market Closed -
Other stock markets
|
After market 05:30:00 am | |||
126.8 USD | +0.84% | 127.3 | +0.36% |
25/04 | NOVO NORDISK : JP Morgan gives a Buy rating | ZD |
25/04 | Scholz promises support for pharma sector in Germany as Merck invests | RE |
Sales 2024 * | 287B 41.21B 0 | Sales 2025 * | 346B 49.58B 0 | Capitalization | 3,955B 567B 0 |
---|---|---|---|---|---|
Net income 2024 * | 104B 14.85B - | Net income 2025 * | 125B 17.9B - | EV / Sales 2024 * | 13.8 x |
Net Debt 2024 * | 23.85B 3.42B 0 | Net cash position 2025 * | 348M 49.96M 0 | EV / Sales 2025 * | 11.4 x |
P/E ratio 2024 * |
38.4
x | P/E ratio 2025 * |
31.6
x | Employees | 63,845 |
Yield 2024 * |
1.33% | Yield 2025 * |
1.59% | Free-Float | 70.47% |
Latest transcript on Novo Nordisk A/S
1 day | +0.36% | ||
1 week | +3.37% | ||
Current month | -1.21% | ||
1 month | -1.98% | ||
3 months | +17.38% | ||
6 months | +33.25% | ||
Current year | +22.62% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 01/91/01 | |
Director of Finance/CFO | 53 | 01/99/01 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 19/15/19 |
Helge Lund
CHM | Chairman | 61 | 23/17/23 |
Martin MacKay
BRD | Director/Board Member | 68 | 01/18/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.75% | 9 M€ | -4.31% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 126.8 | +0.84% | 3,312,457 |
25/24/25 | 125.8 | -0.29% | 3,434,352 |
24/24/24 | 126.2 | -1.93% | 3,143,089 |
23/24/23 | 128.6 | +2.70% | 3,703,606 |
22/24/22 | 125.3 | +2.08% | 3,798,340 |
Delayed Quote Nyse, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B | |
-11.77% | 144B |
- Stock Market
- Equities
- NOVO B Stock
- NVO Stock